OPM reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers

Oncodesign Precision Medicine reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers

Dijon (France), December 20, 2024, at 8:00 am CET– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories.